UPDATED: CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies marred by the death of a patient – Endpoints News

Posted: October 22, 2020 at 3:00 am

From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk of a lightning-fast development campaign in exchange for all the rewards that could fall its way with success. And now that the pharma giant has seized a solid lead in the race to the market, those rewards loom large.

SVB Leerinks Geoff Porges has been running the numbers on Pfizers vaccine, the mRNA BNT162b2 program that the German biotech partnered on. And he sees a $3.5 billion peak in windfall revenue next year alone. Even after the pandemic is brought to heel, though, Porges sees a continuing blockbuster role for this vaccine as people around the world look to guard against a new, thoroughly endemic virus that will pose a permanent threat.

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read the rest here:
UPDATED: CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies marred by the death of a patient - Endpoints News

Related Post

Comments are closed.

Archives